(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
This phase I trial studies the side effects and the best dose of trebananib in treating patients with relapsed or refractory solid tumors, including central nervous system tumors.
This is a multicenter, dose-escalation study (part 1) followed by a safety and imaging study (part 2).
For more information contact: Cincinnati Children’s Hospital Medical Center Division of Hematology/Oncology 3333 Burnet Ave., Cincinnati, OH 45229-3039 Phone: 513-636-2799 email@example.com
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center